lenalidomide has been researched along with 5p Deletion Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arai, A; Miura, I; Sakai, H | 1 |
| Bewersdorf, JP; Zeidan, AM | 1 |
1 review(s) available for lenalidomide and 5p Deletion Syndrome
| Article | Year |
|---|---|
Evolving therapies for lower-risk myelodysplastic syndromes.
Topics: Anemia; Blood Transfusion; Chelation Therapy; Clinical Trials as Topic; Cri-du-Chat Syndrome; Drugs, Investigational; Forecasting; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Iron Overload; Lenalidomide; Molecular Targeted Therapy; Multicenter Studies as Topic; Myelodysplastic Syndromes; Precision Medicine; Prognosis; Risk Assessment; Severity of Illness Index | 2020 |
1 other study(ies) available for lenalidomide and 5p Deletion Syndrome
| Article | Year |
|---|---|
Quantitative evaluation of treatment response to lenalidomide by applying fluorescence in situ hybridization for peripheral blood granulocytes in a patient with 5q- syndrome.
Topics: Aged, 80 and over; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Cri-du-Chat Syndrome; Female; Granulocytes; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Trisomy | 2022 |